Drug Profile
Research programme: cancer therapeutics - Daiichi Sankyo/Vernalis
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; Vernalis
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Cancer in Japan
- 28 Jan 2022 No recent reports of development identified for research development in Cancer in United Kingdom
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals